ReviewInternational journal of molecular sciences2022
Vancomycin-Associated Acute Kidney Injury: A Narrative Review from Pathophysiology to Clinical Application.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 4 syntheses or guidelines pooled it, 116 citations in OpenAlex.
- Genetic and nongenetic factors affecting vancomycin population pharmacokinetics and pharmacodynamics: A systematic review.Indian journal of pharmacology · 2026Pooled it
- Pooled it
- Systematic review and meta-analysis of vancomycin therapeutic level for treatment of vancomycin-sensitive enterococcal infections.British journal of clinical pharmacology · 2025Pooled it
- APASL clinical practice guidelines on the management of acute kidney injury in acute-on-chronic liver failure.Hepatology international · 2024Guideline
- Promising efficacy of oral nano-silymarin formulation on prevention of vancomycin-induced nephrotoxicity: a randomized, triple-blinded, placebo-controlled clinical trial.Naunyn-Schmiedeberg's archives of pharmacology · 2026Trial
- Protective effects of silymarin on preventing vancomycin nephrotoxicity in infectious patients: a randomized, double-blinded, placebo-controlled, pilot clinical trial.Naunyn-Schmiedeberg's archives of pharmacology · 2025Trial
- Model-informed AUC-guided dosing for parenteral vancomycin in critically ill patients: impact on target attainment and renal safety - a pre-post intervention study.BMC pharmacology & toxicology · 2026Article
- Biochanin A ameliorates vancomycin-induced acute kidney injury via modulation of the JAK2/STAT-3/GPX4 axis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Incidence and risk factors of vancomycin-associated nephrotoxicity among neonates in the intensive care unit: a retrospective cohort study.Pediatric nephrology (Berlin, Germany) · 2026Article
- Timing and severity of acute kidney injury in hospitalized adults receiving vancomycin plus NKCC inhibitor with or without piperacillin-tazobactam.Naunyn-Schmiedeberg's archives of pharmacology · 2026Observational
- Intrawound Vancomycin Powder in Surgical Site Infection Prophylaxis: A Comprehensive Review of Mechanisms, Efficacy, Safety, and Clinical Controversies.Advances in therapy · 2026Review
- Article
- Factors Affecting Vancomycin and Piperacillin-Tazobactam-Induced Nephrotoxicity.Journal of clinical medicine · 2026Article
- Vancomycin-induced acute kidney injury in older Chinese patients: a multicenter retrospective cohort study.BMC geriatrics · 2026Article
- Protective Effects of Licorice (Pharmaceuticals (Basel, Switzerland) · 2026Article
- Perspective: Taxonomy of Kidney Diseases and Disorders Related to Nephrotoxic Drug Exposure in Hospitalized Patients.Mayo Clinic proceedings · 2026Article
- Biomarker-Based Diagnosis and Risk Stratification in Sepsis-Associated Acute Kidney Injury: From Molecular Mechanisms to Multimarker Panels.Diagnostics (Basel, Switzerland) · 2026Review
- Effect of Local Administration of Vancomycin to the Wound on Renal and Hepatic Function After Cardiac Surgery in Neonates.Diseases (Basel, Switzerland) · 2026Article
- Comparison of renal function parameters and acute kidney injury incidence between vancomycin monotherapy and vancomycin-fosfomycin combination therapy in patients: a propensity score-matched analysis.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Article
- Precise Construction of an Antimicrobial Peptide Targeting Bacterial Cell Membranes Derived From Natural Peptides.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vancomycin is the most frequently used antibiotic, accounting for up to 35% of hospitalized patients with infection, because of its optimal bactericidal effectiveness and relatively low price. Vancomycin-associated AKI (VA-AKI) is a clinically relevant but not yet clearly understood entity in critically ill patients. The current review comprehensively summarizes the pathophysiological mechanisms of, biomarkers for, preventive strategies for, and some crucial issues with VA-AKI. The pathological manifestations of VA-AKI include acute tubular necrosis, acute tubulointerstitial nephritis (ATIN), and intratubular crystal obstruction. The proposed pathological mechanisms of VA-AKI include oxidative stress and allergic reactions induced by vancomycin and vancomycin-associated tubular casts. Concomitant administration with other nephrotoxic antibiotics, such as piperacillin-tazobactam, high vancomycin doses, and intermittent infusion strategies compared to the continuous infusion are associated with a higher risk of VA-AKI. Several biomarkers could be applied to predict and diagnose VA-AKI. To date, no promising therapy is available. Oral steroids could be considered for patients with ATIN, whereas hemodialysis might be applied to remove vancomycin from the patient. In the future, disclosing more promising biomarkers that could precisely identify populations susceptible to VA-AKI and detect VA-AKI occurrence early on, and developing pharmacological agents that could prevent or treat VA-AKI, are the keys to improve the prognoses of patients with severe infection who probably need vancomycin therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.